Clinical trial
Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
NCT00003041 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003041 |
|---|---|
| Title | Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer |
| Official title | Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pyrazoloacridine |
| Start date | Jul 1, 1997 |
| Completion | Jan 1, 2002 |
| First posted | Apr 23, 2004 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: